View Press Releases
SYMBIOSIS AFFIRMS COMMITMENT TO GROWTH WITH NEW BUSINESS DEVELOPMENT MANAGER FOR THE NORDICS AND GERMANY
Stirling, UK – 8th June 2021: Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, and headquartered in Stirling, UK, has appointed Jette Cowan as Business Development Manager (BDM) for the Northern region of the European Union (E.U.).
As BDM, Jette will be tasked with developing strategic relationships with new and existing clients across the Nordic region and Germany. Co-located in Denmark and the UK, Jette will apply her experience in commercial pharma drug development to engage new customers and deliver programmes that enable clients to bring products quickly and successfully to market.
“Our capabilities in small-to-medium scale clinical and commercial sterile manufacturing continue to resonate successfully in our target markets such as viral vector ATMPs, vaccines and biologic sterile manufacturing, and also with our clients,” Colin MacKay, CEO at Symbiosis. He added: “This is demonstrated by our consistent annual business growth. Recruiting a BDM of Jette’s calibre emphasizes our continued commitment to market development and to growth in the EU specifically, alongside the US and UK.
In the last two years Symbiosis has grown its sterile biologics manufacturing capabilities significantly and invested over £1.5m ($1.9m) in its facility expansion, which doubled its physical footprint and provides additional aseptic manufacturing capacity.
Jette strengths include working with clients to proactively add value to successful drug development programmes. “I am really attracted to Symbiosis’ vision of developing mutually beneficial long-term partnerships with clients – a true symbiotic relationship, hence the name and a brand built on trust,” explained Jette. “My goal is to offer flexibility and excellence in service and create the basis for long term partnerships, not just as a supplier but as a close collaborative partner helping to achieve clinical and commercial milestones together.”
“The company’s culture and vision align perfectly with my own,” said Jette. “Symbiosis is a flexible and fast-growing dynamic company and I’m really excited to be part of the team driving Symbiosis to the next stage and building long lasting collaborative relationships with developers bringing new biologic drugs to market in the Nordics and Germany.”
Jette brings to Symbiosis decades of business development success, plus key experience gained from roles with several prominent European life science companies. Equipped with an MSc in Microbiology & Chemistry, Jette has a consistent track record of creating and developing business opportunities and relationships across the industry.
About Symbiosis Pharmaceutical Services
Symbiosis Pharmaceutical Services Ltd (Symbiosis) is a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) established in 2011 in Stirling, UK, to provide niche sterile manufacturing services to GMP standards and produce injectable products for its clients to use in thier clinical trials or to supply specialist commercial markets.
In 2011, Symbiosis set out to be a UK-located service provider to an international biotechnology and pharmaceutical market and to create wealth and jobs in the life sciences sector in Scotland. The Scottish economic development agency, Scottish Enterprise, was instrumental in supporting the start-up of the company and provided investment capital through its investment arm, the Scottish Investment Bank (SIB).
The company has a manufacturing facility which can manufacture biologic, vaccine, or small-molecule sterile bio/pharmaceutical products for biotechnology and pharmaceutical clients globally who are developing medicines to treat cancers and neurodegereative diseases, for example. The company also has an office in Cambridge, Massachussetts, which services an increasing proportion of US clients.
Manufacturing is undertaken in an FDA-approved and MHRA-licensed facility which is regulated to facilitate the handling of biological products including the latest drug development technologies in the field of Advanced Therapeutic Medicinal Products (ATMPs) such as viral vector-based therapeutic and vaccine products.
For further information, images and interview opportunities with Symbiosis, please contact Rachael Heath at ramarketing I firstname.lastname@example.org I 07592 342866 I 0191 222 1242 I www.ramarketingpr.com